Session » RA – Diagnosis, Manifestations, and Outcomes Poster II

Date: Sunday, November 13, 2022

Time: 9:00AM-10:30AM

Meeting: ACR Convergence 2022

9:00AM-10:30AM: Abstract Number: 0885

Association Between Changes in Inflammatory Pathways Associated with a Reduction in CV Risk: Results from the LiiRA Study

9:00AM-10:30AM: Abstract Number: 0912

Associations Between Fatty Acid Amide Hydrolase Variants and Response to Cannabis Use for Pain Management in Rheumatoid Arthritis

9:00AM-10:30AM: Abstract Number: 0893

ATP-Binding Cassette G1 Membrane Transporter-mediated Cholesterol Efflux Capacity Influences Coronary Atherosclerosis and Cardiovascular Risk in RA

9:00AM-10:30AM: Abstract Number: 0888

Cardiovascular and Thromboembolic Events in Rheumatoid Arthritis Patients Before and After Initiation of a First Advanced Therapy. Data from the University of Sherbrooke Registry of Advanced Therapies (USRAT)

9:00AM-10:30AM: Abstract Number: 0887

Comparison of Drug Persistence and Incidence of Tuberculosis Between Tumor Necrosis Factor-α Inhibitors and Tocilizumab as the First-line Biological Treatment in Patients with Rheumatoid Arthritis Using the Korean Health Insurance Review and Assessment Service Database

9:00AM-10:30AM: Abstract Number: 0895

COVID-19 Vaccination in Autoimmune Diseases Study: Vaccine Safety in Rheumatoid Arthritis

9:00AM-10:30AM: Abstract Number: 0894

DAS28-gGT for the Prediction of Major Cardiovascular Events in Rheumatoid Arthritis: Results from the ESPOIR Cohort

9:00AM-10:30AM: Abstract Number: 0902

Diagnosis of Mental Disorder Complicated by Rheumatoid Arthritis: A Study of the Validity of a Psychiatrist’s Diagnosis and Questionnaire Method

9:00AM-10:30AM: Abstract Number: 0900

Effect of Biologic Agents on Lipid Levels and Cardiovascular Risk in Rheumatoid Arthritis Patients

9:00AM-10:30AM: Abstract Number: 0901

Factors Associated with Household Work Limitations in Mexican Patients with Rheumatoid Arthritis: The Impact of the Disease on Women’s Life

9:00AM-10:30AM: Abstract Number: 0907

Identifying Trajectories of Remission in Patients with Rheumatoid Arthritis Treated in a Tertiary Care Centre

9:00AM-10:30AM: Abstract Number: 0886

Incidence of Depression and Anxiety in Rheumatoid Arthritis Patients over Three Decades: A Population-Based Study

9:00AM-10:30AM: Abstract Number: 0890

Long Term Efficacy of a 2-year MRI Treat-to-target Treatment Strategy on Disease Activity, MRI Inflammation and Physical Function in Rheumatoid Arthritis Patients in Clinical Remission: Five Year Follow-up of the IMAGINE-RA Cohort

9:00AM-10:30AM: Abstract Number: 0906

Patients with Seronegative Rheumatoid Arthritis Have a Different Ultrasound-assessed Joint Disease Phenotype Than Seropositive Patients

9:00AM-10:30AM: Abstract Number: 0911

Peer Coach Intervention to Improve Primary Cardiovascular Disease Screening for Patients with Rheumatoid Arthritis

9:00AM-10:30AM: Abstract Number: 0899

Performance of the Foot Function Index Questionnaire in Patients with Rheumatoid Arthritis

9:00AM-10:30AM: Abstract Number: 0903

Plasma Inflammatory Protein Biomarkers May Predict Cardiovascular Events in Early Rheumatoid Arthritis

9:00AM-10:30AM: Abstract Number: 0905

Predicting Disease Activity in Rheumatoid Arthritis Patients Using Machine Learning: Data from the ACR’s RISE Registry

9:00AM-10:30AM: Abstract Number: 0892

Predicting Value of Circulating Semaphorin 4A for Rheumatoid Arthritis Progression and Response to Treatment

9:00AM-10:30AM: Abstract Number: 0897

Reasons for Multiple Biologic DMARD Switching and Characteristics of “Extreme Treatment Nonresponders” in Rheumatoid Arthritis

9:00AM-10:30AM: Abstract Number: 0891

Rheumatoid Arthritis and the Rheumatic Disease Comorbidity Index (RDCI): Its Impact on Disease Activity

9:00AM-10:30AM: Abstract Number: 0910

Rheumatoid Arthritis Associated Interstitial Lung Disease: The Role of Non-Criteria Autoantibodies

9:00AM-10:30AM: Abstract Number: 0898

Risk of Aortic Stenosis and Undergoing Aortic Valve Replacement in Rheumatoid Arthritis: An Underrecognized Cardiovascular Complication

9:00AM-10:30AM: Abstract Number: 0896

Screening of Lipids in Patients with Rheumatoid Arthritis: Academic Rheumatology Practice Quality Improvement Analysis

9:00AM-10:30AM: Abstract Number: 0889

Serum Adipokines Predict Incident Osteoporotic Fracture in Patients with Rheumatoid Arthritis

9:00AM-10:30AM: Abstract Number: 0884

Serum Calprotectin Can Differentiate Between Sustained Remission and Low Disease Activity States in Rheumatoid Arthritis

9:00AM-10:30AM: Abstract Number: 0883

Serum Cholesterol Loading Capacity on Macrophages Is Dependent on Oxidized Low-density Lipoprotein and Regulated by Seropositivity and C-reactive Protein in Patients with Rheumatoid Arthritis

9:00AM-10:30AM: Abstract Number: 0904

Testing the Hand Function with a Sensor-engineered Glove in Patients with Rheumatoid Arthritis

9:00AM-10:30AM: Abstract Number: 0908

The Association of Cardiovascular Comorbidities with Remission in Rheumatoid Arthritis Patients Undergoing Treatment with Baricitinib and Conventional Synthetic DMARDs: A Post-Hoc Analysis

9:00AM-10:30AM: Abstract Number: 0909

Unsupervised Clustering Analysis of Circulating Molecular Profiles in Rheumatoid Arthritis Patients Defines Precise CV Risk. Effects of TNFi, IL6Ri, and JAKinibs

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].